268 related articles for article (PubMed ID: 22843491)
1. Autologous regulatory T cells for the treatment of type 1 diabetes.
Thompson JA; Perry D; Brusko TM
Curr Diab Rep; 2012 Oct; 12(5):623-32. PubMed ID: 22843491
[TBL] [Abstract][Full Text] [Related]
2. Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.
Volfson-Sedletsky V; Jones A; Hernandez-Escalante J; Dooms H
Front Immunol; 2021; 12():635767. PubMed ID: 33815387
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.
Rosenzwajg M; Churlaud G; Hartemann A; Klatzmann D
Curr Diab Rep; 2014 Dec; 14(12):553. PubMed ID: 25344788
[TBL] [Abstract][Full Text] [Related]
4. Antigen-Specific Treg Therapy in Type 1 Diabetes - Challenges and Opportunities.
Serr I; Drost F; Schubert B; Daniel C
Front Immunol; 2021; 12():712870. PubMed ID: 34367177
[TBL] [Abstract][Full Text] [Related]
5. Type I diabetes-associated tolerogenic properties of interleukin-2.
Chentoufi AA; Gaudreau S; Nguyen A; Sabha M; Amrani A; Elghazali G
Clin Dev Immunol; 2011; 2011():289343. PubMed ID: 21647403
[TBL] [Abstract][Full Text] [Related]
6. FOXP3+ Regulatory T Cell Compartment Is Altered in Children With Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children.
Viisanen T; Gazali AM; Ihantola EL; Ekman I; Näntö-Salonen K; Veijola R; Toppari J; Knip M; Ilonen J; Kinnunen T
Front Immunol; 2019; 10():19. PubMed ID: 30723474
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective.
Yu H; Paiva R; Flavell RA
Immunology; 2018 Feb; 153(2):161-170. PubMed ID: 29155454
[TBL] [Abstract][Full Text] [Related]
8. Continuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetes.
Jaberi-Douraki M; Pietropaolo M; Khadra A
J Theor Biol; 2015 Oct; 383():93-105. PubMed ID: 26271890
[TBL] [Abstract][Full Text] [Related]
9. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.
Tang Q; Adams JY; Penaranda C; Melli K; Piaggio E; Sgouroudis E; Piccirillo CA; Salomon BL; Bluestone JA
Immunity; 2008 May; 28(5):687-97. PubMed ID: 18468463
[TBL] [Abstract][Full Text] [Related]
10. Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.
Dwyer CJ; Ward NC; Pugliese A; Malek TR
Curr Diab Rep; 2016 Jun; 16(6):46. PubMed ID: 27076179
[TBL] [Abstract][Full Text] [Related]
11. Resuscitating adaptive Tregs with combination therapies?
Bresson D; von Herrath M
Novartis Found Symp; 2008; 292():50-60; discussion 60-7, 122-9, 202-3. PubMed ID: 19203092
[TBL] [Abstract][Full Text] [Related]
12. Restoring Regulatory T Cells in Type 1 Diabetes.
Spence A; Tang Q
Curr Diab Rep; 2016 Nov; 16(11):110. PubMed ID: 27664043
[TBL] [Abstract][Full Text] [Related]
13. Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice.
Koprivica I; Vujičić M; Gajić D; Saksida T; Stojanović I
Front Immunol; 2018; 9():3130. PubMed ID: 30687329
[TBL] [Abstract][Full Text] [Related]
14. Self-Transducible Bimodal PDX1-FOXP3 Protein Lifts Insulin Secretion and Curbs Autoimmunity, Boosting Tregs in Type 1 Diabetic Mice.
Amatya C; Radichev IA; Ellefson J; Williams M; Savinov AY
Mol Ther; 2018 Jan; 26(1):184-198. PubMed ID: 28988715
[TBL] [Abstract][Full Text] [Related]
15. Generation of human islet-specific regulatory T cells by TCR gene transfer.
Hull CM; Nickolay LE; Estorninho M; Richardson MW; Riley JL; Peakman M; Maher J; Tree TI
J Autoimmun; 2017 May; 79():63-73. PubMed ID: 28117148
[TBL] [Abstract][Full Text] [Related]
16. Renegade homeostatic cytokine responses in T1D: drivers of regulatory/effector T cell imbalance.
Gupta S; Cerosaletti K; Long SA
Clin Immunol; 2014 Apr; 151(2):146-54. PubMed ID: 24576418
[TBL] [Abstract][Full Text] [Related]
17. Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice.
Kornete M; Mason ES; Girouard J; Lafferty EI; Qureshi S; Piccirillo CA
PLoS One; 2015; 10(5):e0126311. PubMed ID: 25946021
[TBL] [Abstract][Full Text] [Related]
18. Function, Failure, and the Future Potential of Tregs in Type 1 Diabetes.
Bettini M; Bettini ML
Diabetes; 2021 Jun; 70(6):1211-1219. PubMed ID: 34016597
[TBL] [Abstract][Full Text] [Related]
19. Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.
Li CR; Baaten BJ; Bradley LM
J Mol Cell Biol; 2012 Feb; 4(1):38-47. PubMed ID: 22116888
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of TGF-βRII in T effector cells leads to increased resistance to TGF-β-mediated suppression of autoimmune responses in type I diabetes.
Kawamoto K; Pahuja A; Nettles A; Honkanen-Scott M; Bansal-Pakala P
Autoimmunity; 2012 Jun; 45(4):310-9. PubMed ID: 22390157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
